
    
      This study is a randomized trial to compare the outcomes between patients receiving
      neoadjuvant PF-CCRT plus Bevacizumab (BPF-CCRT) or PF-CCRT alone. Investigators design to
      enrol 6 patients in the run-in phase, and 44 patients in the randomized phase (22 patients in
      each group) to develop the preliminary evidence for using Bevacizumab in ESCC.
    
  